November 2, 2022
API Building under Construction at Fukushima Plant Site Meiji Seika Pharma is looking to file Arcturus Therapeutics’ next-generation mRNA vaccine in Japan in the spring of 2023 with an eye towards summer approval. The drug maker is currently in talks...read more